scholarly journals Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA , a multi‐country observational study

2021 ◽  
Author(s):  
Eva Lesén ◽  
Christopher Hewitt ◽  
Evangelos Giannitsis ◽  
Jonatan Hedberg ◽  
Tomas Jernberg ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Observational Study ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Prior Myocardial Infarction

P1932Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
J J Russo ◽  
A T Yan ◽  
S J Pocock ◽  
D Brieger ◽  
R Owen ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Observational Study ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
Post Myocardial Infarction ◽  
P Value ◽  
Multivariable Logistic Regression Analysis ◽  
History Of ◽  
Esc Guidelines ◽  
Artery Disease

Abstract Background International guidelines vary in their recommendations for dual antiplatelet therapy (DAPT) use beyond 1 year post-myocardial infarction (MI). Purpose To identify predictors of DAPT use in patients ≥1 year post-MI prior to the publication of the DAPT score and the 2017 European Society of Cardiology (ESC) guidelines for DAPT in coronary artery disease. Methods TIGRIS (NCT01866904) was a prospective, multi-center (369 centers in 25 countries), observational study of patients 1 to 3 years post-MI between June 2013 and November 2014. We performed a multivariable logistic regression analysis to identify independent predictors of DAPT use at 396 days post-MI (365 + 31 days overrun period to allow intended DAPT discontinuation at 1 year). Patients on oral anticoagulation were excluded. Results Of 8464 patients enrolled (mean age 66 years, women 24%, ST-elevation MI 53%), 40% were on DAPT at 396 days post-MI (Figure). In the subset of patients on DAPT at 396 days post-MI, aspirin was combined with clopidogrel in 84%, prasugrel in 12%, and other antiplatelet agents in 4%. DAPT use at 396 days post-MI was independently associated with geographic region, age, PCI for the index MI, and a history of multivessel disease or angina (Table). Several variables included in the DAPT score and ESC guideline recommendations (diabetes, second prior MI, hypertension, peripheral artery disease, heart failure, smoking, and renal insufficiency) were not independent predictors of DAPT use at 396 days. Independent predictors of DAPT @396 days Variable at enrolment Patients Odds ratio (95% CI) P-value Region: Europe 3813 Reference group 0.01 North America 923 1.65 (0.56, 4.86) Latin America 1084 2.55 (1.19, 5.47) Asia and Australia 2644 3.01 (1.42, 6.36) Age <65 years 3274 1.15 (1.04, 1.28) 0.005 PCI for index MI 6925 2.08 (1.82, 2.38) <0.0001 Multi-vessel disease 5598 1.37 (1.24, 1.52) <0.0001 History of angina 829 1.46 (1.24, 1.71) <0.0001 DAPT use at 396 days post-MI by region Conclusion During the study period, DAPT use ≥1 year post-MI was prevalent and appeared to be influenced by regional practices. Further research is needed to determine whether the DAPT score and the 2017 ESC guidelines for dual antiplatelet therapy have changed long-term DAPT use practices. Acknowledgement/Funding AstraZeneca AB, Södertälje, Sweden

Dual antiplatelet therapy prolongation in high-risk patients with prior myocardial infarction: insights from the post-PCI registry

2020 ◽  
Vol 21 (8) ◽  
pp. 603-609 ◽  
Author(s):  
Marco Ferlini ◽  
Roberta Rossini ◽  
Giuseppe Musumeci ◽  
Stefano Cornara ◽  
Alberto Somaschini ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
High Risk ◽  
Antiplatelet Therapy ◽  
Dual Antiplatelet Therapy ◽  
High Risk Patients ◽  
Prior Myocardial Infarction ◽  
Risk Patients
Sign in / Sign up

Export Citation Format

Share Document